HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

por Ow, Saw Yen, Kapp, Eugene A., Tomasetig, Vesna, Zalewski, Anton, Simmonds, Jason, Panousis, Con, Wilson, Michael J., Nash, Andrew D., Pelzing, Matthias
Publicado 2023

A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus

por Oon, Shereen, Monaghan, Katherine, Ng, Milica, Hoi, Alberta, Morand, Eric, Vairo, Gino, Maraskovsky, Eugene, Nash, Andrew D, Wicks, Ian P, Wilson, Nicholas J
Publicado 2019

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors

por Panousis, Con, Dhagat, Urmi, Edwards, Kirsten M., Rayzman, Veronika, Hardy, Matthew P., Braley, Hal, Gauvreau, Gail M., Hercus, Timothy R., Smith, Steven, Sehmi, Roma, McMillan, Laura, Dottore, Mara, McClure, Barbara J., Fabri, Louis J., Vairo, Gino, Lopez, Angel F, Parker, Michael W., Nash, Andrew D., Wilson, Nicholas J., Wilson, Michael J., Owczarek, Catherine M.
Publicado 2015